CAPRELSA (vandetanib) is a kinase inhibitor used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. CAPRELSA can also be used to treat a patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA. It is approved by the Food and Drug Administration (FDA).
Manufacturer : AstraZeneca
Strengths available : 100mg & 300mg
Storage : Store at temperature between 15°C -25°C
Dosage : The recommended dose of CAPRELSA is 300 mg taken orally once daily until disease progression or unacceptable toxicity occurs.
Most Common side effects may be Diarrhea, Rash, Elevated Liver Enzymes (ALT), Low calcium levels, Acne, High blood pressure, Nausea, Headache, Fatigue, Low blood sugar, Abdominal pain, Poor appetite, Low white blood cell count, Kidney problems, Dry skin, Vomiting, Weakness, Irregular, heart beat, Insomnia (difficulty sleeping), Photosensitivity (sensitivity to sunlight), Bleeding, Anemia, Liver tests increased (bilirubin), Itching, Heartburn, Cough, Upper respiratory infection, Depression, Weight loss.